These multiple mutations enhance PI3K pathway signaling and are associated with an increased response to PI3K inhibitors, particularly in breast cancer, highlighting the significance of these mutations in oncogenic processes.7, 8. This evidence concerns the gene PIK3CA and breast carcinoma.